Prognosis and Management of Alzheimer

Although the focus of many physicians is the management of (Alzheimer's Disease) AD with cholinesterase inhibitors (ChEI), it is crucial that physicians develop a global management strategy for their patients with AD and their caregivers. Global management includes early accurate diagnosis and providing counselling and pharmacological treatment to the patient and the family/ caregiver. The patient and family must agree with the physician on the treatment ultimately selected for use; this decision must include duration and cost considerations. Both the patient’s premorbid functioning and potential impact on their quality of life must be taken into account when making any treatment decisions for AD patients. A thorough evaluation of comorbid medical and psychiatric disorders and a review of current medications (including discontinuation of unnecessary or harmful medications) are important. As over-the-counter products are popular, physicians are encouraged to ask about their use and to provide appropriate counsel regarding their safety and efficacy. During the evaluation phase, emphasis must be placed on establishing a good rapport with the patients and their families. Regularly scheduled visits, every 1–2 months initially and then every 3 months, for health maintenance and routine patient assessment will assist in maximizing independence and functioning and will minimize behavioral disturbances associated with the progression of the disease. Families with early-onset familial AD may be encouraged to enroll in a research database for potential future curative therapies.

Scholars Alzheimer's conferences bring together all types of people who are affected by dementia - living with the disease, caring for someone with the disease or working in the field of dementia - and give delegates the opportunity to share and exchange their experience and knowledge.